Clostridium Difficile

Community Acquired Clostridium difficile: Significance, Prevalence and Opportunities in the Biotechnology Industry

(Webinar length:  1h 39m)

There are an estimated 25, 000 deaths each year within North America linked to Clostridium difficile infections (CDI). The economic burden of CDI is estimated to be $10B per year with the C difficile control sector market being in the order of $7B and growing. Traditionally C difficile was considered to be exclusively linked to hospital-acquired infections primarily affecting the elderly or those with weakened immune system being administered antibiotics. Here, the antibiotics disrupt the gastrointestinal tract microflora thereby enabling the drug resistant C difficile to proliferate and produce toxins leading to potentially fatal diarrhea. Over the last 3 years there has been an increasing occurrence of Community Acquired C difficile infections and are thought to account for over 40% of all CDI reported. The case definition of Community Acquired CDI is patients who have no recent contact with health care facilities or taking antibiotics. There are many aspects of Community Acquired CDI that remain unknown and especially with relation to sources of the pathogen. 

The following webinar will provide an overview of how C difficile evolved from a harmless commensal to one of the most significant human pathogens. Focus will be made on the emergence and spread of the hospital epidemic strain (NAP-1/027). The emergence of other C difficile strains will be described and their association with Community Acquired infections. Evidence for foodborne, environmental and zoonotic transfer of C difficile will be reviewed. The significance of C difficile as a foodborne pathogen will be discussed. Finally, the opportunities in developing more effective C difficile diagnostic and control methods will be outlined along with research needs in the area.

Areas covered in the webinar:

  • Description and emergence of Clostridium difficile
  • Pathogenicity and global spread of hospital required CDI
  • The rise of Community Acquired CDI
  • Transmission of C difficile via foods, environment and zoonotic transfer
  • Significance of foodborne C difficile
  • Opportunities for the biotechnology industry to develop C difficile diagnostic and control technologies.

Who will benefit:

  • Government policy and risk assessors
  • Health care managers
  • Diagnostic developers
  • Biotechnology scientists
  • QA and QC managers
  • HACCP coordinators

Presenter – Dr. Keith Warriner

Dr. Keith Warriner is currently an Associate Professor within the Department of Food Science at University of Guelph, Canada. Dr. Warriner received his BSc in Food Science from the University of Nottingham, UK and PhD in Microbial Physiology from the University College of Wales Aberystwyth, UK. He later went on to work on biosensors within the University of Manchester, UK and subsequently returned to the University of Nottingham to become a Research Fellow in Food Microbiology. He joined the Faculty of the University of Guelph in 2002. During the last fifteen years in the field of microbiology and food safety research, Dr. Warriner has published more than 100 papers, book chapters, patents, and conference abstracts. He has broad research areas encompassing development of decontamination technologies, biosensors for biohazard detection, and more fundamental research on the interaction of human pathogens with plants. He developed a decontamination treatment for sanitizing seeds and inactivating pathogens on fresh produce and is currently developing other biocontrol strategies.

  • Item #: 1027bCD
  * Marked fields are required.
Price $289.00